Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease
2011

A New Approach to Alzheimer's Therapy Using a Targeted Protease

Sample size: 8 publication 10 minutes Evidence: high

Author Information

Author(s): Spencer Brian, Marr Robert A., Gindi Ryan, Potkar Rewati, Michael Sarah, Adame Anthony, Rockenstein Edward, Verma Inder M., Masliah Eliezer

Primary Institution: University of California San Diego

Hypothesis

Can a CNS targeted protease reduce Aβ toxicity in a mouse model of Alzheimer's disease?

Conclusion

The study found that a targeted protease significantly reduced Aβ levels and improved memory deficits in a mouse model of Alzheimer's disease.

Supporting Evidence

  • Treated mice had reduced levels of Aβ and increased synaptic density.
  • Mice receiving the targeted protease showed a reversal of memory deficits.
  • The approach allows for non-invasive delivery of therapeutic proteins across the blood-brain barrier.
  • Immunohistochemical analysis confirmed widespread uptake of the protease in the CNS.
  • Significant reductions in amyloid plaques were observed in treated mice.

Takeaway

Researchers created a special protein that helps reduce harmful substances in the brain of mice with Alzheimer's, making them remember better.

Methodology

The study used lentivirus vectors to deliver a neprilysin enzyme fused with a transport domain to mice, followed by analysis of Aβ levels and memory tests.

Limitations

The study was conducted in a mouse model, which may not fully replicate human Alzheimer's disease.

Participant Demographics

6-month-old APP transgenic mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016575

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication